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Background: Cisplatin (CDDP) resistance in testicular germ cell tumors (GCTs) is still a clinical challenge, and one
associated with poor prognosis. The purpose of this work was to test pazopanib, an anti-tumoral and
anti-angiogenic multikinase inhibitor, and its combination with lapatinib (an anti-ErbB inhibitor) in mouse
orthotopic models of human testicular GCTs.
Methods: We used two different models of human testicular GCTs orthotopically grown in nude mice;
a CDDP-sensitive choriocarcinoma (TGT38) and a new orthotopic model generated from a metastatic GCT refractory
to first-line CDDP chemotherapy (TGT44). Nude mice implanted with these orthotopic tumors were treated with
the inhibitors and the effect on tumoral growth and angiogenesis was evaluated.
Results: TGT44 refractory tumor had an immunohistochemical profile similar to the original metastasis, with
characteristics of yolk sac tumor. TGT44 did not respond when treated with cisplatin. In contrast, pazopanib had an
anti-angiogenic effect and anti-tumor efficacy in this model. Pazopanib in combination with lapatinib in TGT38, an
orthotopic model of choriocarcinoma had an additive effect blocking tumor growth.
Conclusions: We present pazopanib as a possible agent for the alternative treatment of CDDP-sensitive and
CDDP-refractory GCT patients, alone or in combination with anti-ErbB therapies.
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Germ cell tumors (GCTs) of the testis are an uncommon
malignancy, but constitute the most frequent cancer type
among men aged between 15 and 35 years [1]. GCTs can
be divided into seminoma or non-seminoma tumors on the
basis of histological, biological and clinical features. Non-
seminoma GCTs may consist of several distinct histological
components (such as teratoma, embryonal carcinoma, yolk
sac tumor and choriocarcinoma) or combinations thereof
[2], and while almost all seminomas are curable with orchi-
ectomy, non-seminomas frequently require chemotherapy
and surgery, and are less sensitive to radiotherapy [3].
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reproduction in any medium, provided the orachieve a complete response with first-line chemotherapy
based on CDDP, alone or combined with surgery. How-
ever, some patients do have late relapses, which are usually
chemotherapy-resistant, or refractory diseases following
their first-line chemotherapy. Treatment of these patients
consists in most cases of second-line CDDP-based chemo-
therapy and radical surgery, which only occasionally pro-
duces durable responses [3-6]. Therefore, new alternative
therapies for refractory and resistant patients are needed.
Angiogenesis, the recruitment of new blood vessels, is
essential for tumor growth and metastasis, and is driven
by a balance between anti-angiogenic and pro-angiogenic
factors. VEGF and PDGF are two of several molecules that
promote angiogenesis by binding to specific cell-surface
tyrosine kinase receptors (TKRs) [7,8]. Anti-angiogenic
therapies have shown efficacy in the treatment of various
tumor types, directly targeting VEGF (such as the antibody
bevacizumab) as well as the combined inhibition of
VEGFRs and PDGFRs by multitarget tyrosine kinasel Ltd. This is an Open Access article distributed under the terms of the Creative
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cular invasion [11], and previous studies have described the
involvement of c-KIT, PDGFRs, VEGFRs and their ligands
in the tumorigenesis of the GCTs of the testis [11-15].
Pazopanib (GW786034) is an oral multikinase inhibi-
tor that targets the TKRs VEGFR1, VEGFR2, VEGFR3,
PDGFRα, PDGFRβ and c-KIT [16,17]. Pre-clinical in vivo
studies of pazopanib have shown it to inhibit VEGF-
induced angiogenesis, tumor angiogenesis and the growth
of several human tumor xenografts (multiple myeloma,
colon, melanoma, prostate, kidney, breast and lung tumors)
in mice [16,18]. Pazopanib has been shown to have signifi-
cant clinical benefit in several phase II and III studies in a
wide variety of malignancies, including soft tissue sarcoma,
thyroid cancer, ovarian cancer, non-small cell lung cancer
[19-23], and in patients with metastatic renal cell carcinoma
(RCC) [19,24]. Pazopanib was approved by the US FDA for
the treatment of patients with advanced RCC in 2009 [25]
and was conditionally approved by the European Medicines
Agency in 2010.
In the present study we evaluate the efficacy of pazopanib
in two models of human testicular GCTs orthotopically
grown in nude mice: a CDDP-sensitive choriocarcinoma
and a new orthotopic model originated from a metastatic
GCT that is refractory to first-line CDDP chemotherapy.
Moreover we tested pazopanib alone or in combination
with the anti-ErbB inhibitor lapatinib.Methods
Chemical compounds
Pazopanib (Votrient®) and Lapatinib (Tyverb®) were
provided by GlaxoSmithKline. Both were dissolved in 0.5%
carboxymethylcellulose – 0.1% Tween 80 (Sigma) solution.
CDDP was provided by the Pharmacological Department
of our institution; it was diluted in sterile serum before in-
traperitoneal injection. Drug aliquots were prepared once
weekly and kept in the dark at 4°C.Orthotopic implantation of testicular tumors
Male nu/nu Swiss mice were purchased from Harlan
(Spain). Mice were housed and maintained in laminar
flow cabinets under specific pathogen-free conditions. All
the animal studies were approved by the local committee
for animal care (IDIBELL, Ref. PR218/09).
The testicular GCTs used were perpetuated in nude
mice by consecutive passages. We used two orthotopic
testicular GCTs models for our studies; a choriocarcinoma
(TGT38), previously described by Castillo-Avila et al. [26],
and TGT44, originated from a human retroperitoneal
metastatic mixed GCT with teratoma and yolk sac com-
ponents. This tumor was originally refractory to first-line
CDDP chemotherapy, and the yolk sac component is able
to grow in nude mice.For the surgical implantation, mice were anesthetized by
isoflurane inhalation. A small midline incision was made
and the testes were exteriorized. A piece of 2–4 mm3
tumor was implanted in each testis using Prolene 7.0
surgical sutures. The testes were returned to the ab-
dominal cavity and the incision was closed with wound
clips. Meloxicam was administered subcutaneously to
the mice (5 mg/kg) the day of the surgical intervention
and for two days after implantation.
For the first two passages of TGT44, mice bearing this
orthotopic tumor were treated with three doses of 4 mg/kg
CDDP as a first CDDP resistance test. No difference in time
of tumoral growth was observed between CDDP-treated
mice and vehicle-treated mice.
Treatment schedule
As the tumors had different growth behaviors the treatment
schedules were different for TGT38 and TGT44. For
both tumors, treatments started when a palpable intra-
abdominal mass was detected; studies were terminated
when tumors in vehicle-treated animals were judged to
be adversely affecting their wellbeing.
The treatment of mice bearing the TGT44 tumor
started six weeks after tumor implantation and continued
for six more weeks. Four mice were treated with pazopanib,
administered daily with gavage as an oral dose of 100 mg/kg
[16], while oral vehicle solution was administered daily by
gavage to the control group (three mice). Three mice were
treated with four doses of 4 mg/kg CDDP, administered
intraperitoneally once a week for the first four weeks.
Control group mice received intraperitoneal sterile serum
with the same schedule as CDDP mice.
Regarding TGT38 tumor, treatment started 13 days
after tumor implantation. Twelve mice were treated
with pazopanib, administered daily with an oral dose of
100 mg/kg, as previously described by Kumar et al.
[16]. Thirteen mice were treated daily with 100 mg/kg
lapatinib, administered orally [27]. For the pazopanib/
lapatinib combination group, twelve animals were treated
daily with pazopanib (100 mg/kg) and lapatinib (100 mg/kg),
administered orally. Eighteen mice were treated with vehicle
oral solution with the same schedule as the treated groups.
Mice were treated for 14 days.
These treatments had no significant effect on mouse
body weight and the animals appeared healthy and
active throughout the study. Mice were sacrificed by
CO2 inhalation and the effects of the different treat-
ments on tumor response were evaluated by determin-
ing tumor weight and volume, where volume=(length)
(width2/2). In order to show whether single and com-
bined treatments have toxic effect, an apoptotic cell
analysis in liver was perfomed in control and treated
mice. The results obtained showed lack of toxic effects
of all treatments.
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and pazopanib in the combination treatment group, we
calculated the combination ratio (CR), as described
elsewhere [28]. The fractional tumor volume (FTV) for
each treatment group was calculated as the ratio of the
mean volumes of treated to control tumors, giving values
for FTVlapatinib, FTVpazopanib and FTVlapatinib+pazopanib.
The expected FTV for the combination group was de-
fined as observed FTVlapatinib x observed FTVpazopanib.
The ratio of expected FTVlapatinib+pazopanib / observed
FTVlapatinib+pazopanib is the CR. We concluded that
values of CR>1 indicated supra-additive effects, while
values of CR<1 indicated infra-additive effects.Immunofluorescence studies
OCT-frozen tissue sections (3 μm) from control and
pazopanib-treated tumors were used for immunofluores-
cence vessel staining. Sections were fixed with 4% parafor-
maldehyde for 10 min and then washed once with distilled
water and twice with PBS 0.1% Triton X-100. These were
then incubated overnight at 4°C with a 1:50 dilution of rat
monoclonal antibody for CD31 (BD Pharmingen). Sections
were washed twice with PBS 0.1% Triton X-100 and incu-
bated with a 1:200 dilution of Alexa Fluor 488-conjugated
goat anti-rat at room temperature for 1 h in the dark.
TGT38 tumor slides were washed twice in PBS 0.1% Triton
X-100 and incubated with a 1:1000 dilution of TO-PRO-3
(Molecular Probes) for 30 min in the dark. Finally, the slides
were washed twice in PBS, and coverslips were mounted
using Gel Mount aqueous mounting medium (Sigma).
TGT44 tumor sections were mounted using VectaShield
mounting medium for fluorescence with DAPI.
Images of TGT38 sections were obtained on a Leica TCS
SL spectral confocal microscope and images of TGT44 on
an Olympus BX60 microscope. To determine vessel density
the ratio of the CD31-stained area to the total area and the
number of vessels in each area were quantified. Quantifica-
tions were carried out in six hotspot fields of viable tissue
zones at 400x magnification for each tumor, using Image J
software. An average value for each tumor was obtained for
each variable. Results are expressed as the means for each
treatment group.Histological study
Representative fragments of the primary and xenografted
tumors were fixed in buffered formalin, dehydrated and
embedded in paraffin. Tissue sections (3–4 μm) were
stained with hematoxylin-eosin for morphological analysis.
Anti-EMA mouse monoclonal antibody (1:200, Dako,
clone E29, M0613), anti-Cam5.2 mouse monoclonal anti-
body (ready-to-use, Becton Dickinson, ref 345779), anti-AFP
rabbit polyclonal antibody (ready-to-use, Dako, IR500)
and anti-c-KIT (CD117) rabbit polyclonal antibody(1:750, Dako, A4502) were used for immunohistochemical
characterization.
Antigen retrieval was performed in the Dako PT Link
using the high pH Dako retrieval solution (K8004) for
AFP and c-KIT, and the low pH Dako retrieval solution
(K8005) for Cam5.2 and EMA for 20 min at 95°C. The
slides were stained on an Autostainer Link 48 (Dako).
The EnVisionTMFlex+ detection system (Dako, Glostrup,
Denmark, K8002) was used for visualization. Sections were
incubated for 5 min with peroxidase-blocking reagent
(SM801), 20 min with the primary antibody, 20 min with
the EnVision™ FLEX/HRP Detection Reagent (SM802), 10
min with EnVision™ FLEX DAB+ Chromogen (DM827)/
EnVision™ FLEX Substrate Buffer (SM803) mix and 5 min
with EnVision™ FLEX Hematoxylin (K8008). The slides
were then dehydrated and mounted.
Western blotting
Samples from two fragments of TGT44 tumor were
mechanically disrupted using RIPA lysis buffer (0.1% SDS,
1% NP-40, 0.5% sodium deoxycholate, 50 mM NaF, 5 mM
EDTA, 40 mM β-glycerophosphate, 200 μM sodium
orthovanadate, 100 μM phenylmethylsulfonyl fluoride,
1 μM pepstatin A, 1 μg/ml leupeptin, 4 μg/ml aprotinin in
PBS, pH 7.4) and a glass homogenizer on ice. Insoluble
material was removed by centrifugation at 12,000 X g for
10 min at 4°C. Protein concentration was determined using
a BCA assay kit (Pierce). Proteins from tumor lysates were
separated on a 7.5% acrylamide-SDS gel and electrophoretic-
ally transferred to an Immobilon-P membrane (Millipore,
Billerica, MA) in 25 mM Tris–HCl, 0.19 M glycine, 10%
methanol. The membrane was blocked in TBS (150 mM
NaCl, 50 mM Tris, pH 7.4) containing 5% non-fat dry milk
for 1 h. Blots were incubated with 1/500 polyclonal goat
anti-human PDGFRα antibody (RαD systems), 1/500
polyclonal rabbit anti-human PDGFRβ (P-20) antibody
(Santa Cruz Biotechnology, Inc.) or 1/1000 monoclonal
mouse anti-tubulin antibody (Sigma Chemical, St Louis,
MO) in TBS 1% non-fat dry milk overnight at 4°C. After
washing in TBS 0.1% Triton X-100, blots were incubated
with 1/2500 anti-goat IgG (Dako) antibody, 1/2500
anti-rabbit IG or 1/5000 anti-mouse IG (Amersham
Pharmacia Biotech, Cambridge, UK) horseradish peroxidase
linked antibodies, in TBS 1% non-fat dry milk at room
temperature for 1 h and after washing in TBS 0.1% Triton
X-100, blots were developed with an enhanced chemilu-
minescence system (Amersham Pharmacia Biotech).
Quantitative real-time PCR
Total RNA from tumors was extracted using the RNAeasy
Plus Mini Kit (Qiagen) and cDNA obtained after a reverse
transcription reaction (High Capacity cDNA Reverse
Transcription Kit, Applied Biosystems). Real-time PCR of
cDNA obtained from TGT44, TGT1, TGT38 independent
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as described elsewhere [26]. Human-specific primers
used were PDGFRα (5′- AGTTCCTTCATCCATTCT
GGACT and 5′- CCGTCTGTCCCCCAGTT), PDGFRβ
(5′-CATCACCGTGGTTGAGAGC and 5′-AATTGTAG




Statistical analysis was carried out with SPSS for Windows
(version 13.0, SPSS, Inc., Chicago, IL). Statistical signifi-
cance of differences in tumor growth or CD31 expression
between different treatment groups was determined using
the two-tail Mann–Whitney U test. In all experiments,
differences were considered statistically significant for
values of p < 0.05.
Results
TGT44 CDDP-refractory tumor model characterization
As already mentioned, the main objective of our work
was to find new therapeutic possibilities not only for pa-
tients who had become resistant after CDDP treatment,
but also for patients directly refractory to this treatment.
In a previous article [26], we presented data obtained from
a model of CDDP-resistant testicular GCT (TGT38R) gen-
erated in our laboratory after the administration of several
doses of in vivo cisplatin. In order to generate an equivalent
testicular GCT mouse model, in this case for CDDP-
refractory tumors, we orthotopically implanted a human
retroperitoneal metastatic mixed GCT (with teratoma and
yolk sac components) that was refractory to first-line
CDDP chemotherapy. The yolk sac component grew in the
mice and generated TGT44. After orthotopic implantation
of this primary tumor in mice, animals were subjected to
CDDP treatment as a first test of CDDP resistance. No
difference in time of tumor growth was observed after
CDDP treatment, confirming that TGT44 retains refractiv-
ity to CDDP treatment (data not shown).
A histological analysis was performed to characterize
the retroperitoneal surgical specimen and to compare
it with the orthotopic tumor before and after treatment
with CDDP. The yolk sac component of the surgical sam-
ple, as well as of the orthotopic tumor before CDDP treat-
ment in mice showed solid and focally microcystic
patterns (Figure 1A, a, b, d and e), whereas the orthotopic
CDDP-treated tumor had a predominantly solid yolk sac
pattern (Figure 1A, c and f). The immunohistochemical
profile was similar in the original metastasis and the two
orthotopic tumors, and was characteristic of a yolk sac
tumor with extensive expression of cytokeratine Cam5.2
(Figure 1A, g, h and i), but with only focal expression of
EMA (Figure 1A, j, k and l) and patchy immunoreactivity
for AFP (Figure 1A, m, n and o).Our next objective was to evaluate the efficacy of
pazopanib in the TGT44 CDDP-refractory model of
testicular GCT. Thus, we first studied the presence of dif-
ferent pazopanib targets in these tumors. TGT44 presented
vascular structures, positive for CD31 (an endothelial
marker), but fewer of them than in, for example,
choriocarcinoma tumors (Figure 1A). c-KIT tyrosine kinase
receptor was detected by immunohistochemistry in the
TGT44 and primary tumors (Figure 1B). Moreover,
PDGFRα and PDGFRβ expression was detected by
western blot in TGT44 tumors (Figure 1C), confirming
that these two pazopanib targets were also present in
the tumor. In order to confirm tumoral expression of
these receptors, specific human PDGFRα and PDGFRβ
mRNA levels were analyzed in TGT44. We also mea-
sured their levels in other orthotopic testicular tumor
models, such as TGT1 and TGT38, wherein the ex-
pression of mRNAs has already described [26], and in
two testicular tumoral cell lines, the embryonal carcin-
oma GCT27 cell line [29] and the yolk sac 1411H cell
line [30]. When we compared the mRNA levels of these
samples we observed that TGT44 expressed both
hPDGFRα and hPDGFRβ (Figure 1D).
Pazopanib has anti-tumor and anti-angiogenic activity in
TGT44 orthotopic CDDP-refractory human tumor model
Having confirmed that the pazopanib targets were expressed
in TGT44, mice bearing this tumor were randomized into
three groups and treated with vehicle, CDDP or pazopanib.
CDDP resistance was confirmed when no significant inhib-
ition of tumor volume was observed after mice were treated
with CDDP (Figure 2). However, the final tumor volume of
the mice treated with pazopanib was significantly smaller
than in the control group (Figure 2).
Sections of tumors were further subjected to CD31
staining to evaluate the tumor vascular endothelium. The
ratio of the CD31-stained area to the total area of tumor
sections from both treatment groups (Figure 3A) were
analyzed, as well as the number of vessels in a viable
tumor area (Figure 3B). Pazopanib induced a significant
reduction in tumor vascular density and the number of
vessels in TGT44, confirming its anti-angiogenic activity
in the TGT44 tumor model.
Pazopanib inhibits tumor growth and synergizes with
lapatinib anti-ErbB treatment in an orthotopic model of
testicular choriocarcinoma
We recently showed that testicular cancer cells are very
sensitive to dual anti-ErbB1 and anti-ErbB2 inhibitors
such as lapatinib, in contrast with the very weak effect
obtained with pure anti-ErbB1 inhibitors [31]. We found
the same effect in vivo in an orthotopic model of human
choriocarinoma [31]. To establish whether there was any
synergistic effect of pazopanib and lapatinib, we selected
Figure 1 Immunohistochemical analysis and expression of pazopanib targets in TGT44. A) Histological and immunohistochemical
characterization of TGT44, CDDP-treated TGT44 (with three injections of 4 mg/kg CDDP) and the original tumor biopsy: (a-f) Hematoxylin-eosin
staining (a-c: 150x, bar 100 μm; d-f: 400x, bar 100 μm); (g-i) CAM5.2 immunostaining; (j-l) EMA immunostaining; (m-o) AFP immunostaining. 400x,
bar 100 μm. B) c-KIT expression in TGT44 and original tumor biopsy was characterized by immunohistochemical analysis. 400x, bar 100 μm.
C) Expression of PDGFRα and PDGFRβ receptors, and tubulin as a loading control, was analyzed by western blot of two TGT44 independent
tumors. D) mRNA levels of human PDGFRα and PDGFRβ were analyzed by quantitative real-time PCR in TGT44, TGT1, TGT38 orthotopic tumor
models, and in GCT27 and 1411H testicular cell lines. Results are expressed as 2(−ΔCt)·104 (with SD).
Figure 2 Pazopanib inhibits tumor growth in a xenograft
orthotopic model of CDDP-primary refractory yolk sac
testicular germ cell tumor. Mice with an orthotopically implanted
TGT44 CDDP-refractory yolk sac tumor were treated with vehicle,
four injections of 4 mg/kg CDDP or daily 100 mg/kg pazopanib for
six weeks. Mice were sacrificed when control mouse tumors affected
the wellbeing of the animals. Final volumes are illustrated by a
boxplot. *, p < 0.05 (two-tail Mann–Whitney U test).
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et al. [26], which reproduces the histological and genetic
characteristics of the original choriocarcinoma primary
testicular tumor. Mice with orthotopically implanted
TGT38 were treated with vehicle, pazopanib, lapatinib or
the pazopanib/lapatinib combination. These treatments
had no significant effect on mouse body weight or toxicity
in liver and the animals appeared healthy and active
throughout the study (Additional file 1: Figure S1). Their
tumor volumes were determined at the end of the experi-
ment (Figure 4). As previously described, lapatinib treatment
caused a significant decrease in tumor volume relative to
the control group. Pazopanib treatment also significantly
inhibited the increase in tumor volume compared with the
control group. The effect of treating the animals with both
inhibitors was greater than when the inhibitors were admin-
istered separately (Figure 4). Moreover, values of the com-
bination ratio (CR) were greater than 1, indicating that the
combination treatment had supra-additive effects.
Pazopanib reduces tumor vascular density
To assess the effects of the different inhibitors on tu-
moral vasculature, the tumoral vascular endothelium
Figure 3 Pazopanib displays antiangiogenic activity in a CDDP-refractory model of testicular GCT. A) Percentage CD31-stained area in a
viable tumor area and B) number of vessels in a viable tumor area were quantified using Volocity software. Means and SDs of six sections of each
tumor were determined as the positive CD31-stained area relative to the control group. *, p < 0.05 (two-tail Mann–Whitney U test).
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endothelial marker CD31 (Figure 5A). The percentage of
CD31-stained area to the total tumor area (Figure 5B) and
the number of vessels in viable tumor zones (Figure 5C)
were measured. Lapatinib treatment did not significantly
affect either of these characteristics. In contrast, pazopanib
treatment caused a significant decrease in both variables,Figure 4 Pazopanib inhibits tumor growth in a xenograft orthotopic
synergizes with lapatinib. Mice orthotopically implanted with the TGT38
100 mg/kg lapatinib or a combination of both for 14 days. Final tumor volu
Mann–Whitney U test). All treatments showed significant inhibition with rethe effect being maintained when pazopanib was adminis-
trated with lapatinib.
Discussion
Our results show that pazopanib as a single agent has
anti-tumor and anti-angiogenic activity in preclinical
models of CDDP-sensitive and CDDP-refractory testicularmodel of choriocarcinoma testicular germ cell tumor and
choriocarinoma were treated daily with vehicle, 100 mg/kg pazopanib,
mes are illustrated by a boxplot. **, p < 0.01; ***, p < 0.001 (two-tail
spect to the control group.
Figure 5 Pazopanib reduces vessel density in a xenograft orthotopic model of choriocarcinoma testicular germ cell tumor. (A) Staining
for CD31 endothelial marker was carried out in viable zones of TGT38 choriocarcinoma tumors implanted in mice and treated as in Figure 4. Bar
40 μm, 400x. CD31 expression was analyzed by measuring the percentage of area with positive CD31 staining in a viable tumor area (B) and the
number of vessel structures (C). Quantification was carried out using Image J software. The means and SDs of six sections of each tumor (four
tumors per treatment group) of each variable are shown. *, p < 0.05 (two-tail Mann–Whitney U test).
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ErbB2 inhibitor lapatinib had a synergistic effect on tumoral
growth. These results further confirm and extend our
previous results with sunitinib [26]. Nevertheless, it is
important to stress that the previous study showed
sunitinib efficacy in a CDDP-resistant xenograft GCT
model (TGT38R). That model was generated in our labora-
tory by prolonged CDDP treatment of mice bearing the
primary tumor. In contrast, the CDDP-resistant testicular
tumor model used in this study (TGT44) came from a pa-
tient with a CDDP-refractory metastatic testicular tumor.
We have shown that this tumor retained CDDP resistance
after transfer from the patient to the orthotopic animal
model. Moreover, no significant histological differ-
ences were observed between the primary and the
orthotopically implanted tumor, even after treatment
with CDDP. Thus, this new testicular in vivo tumor
model offers new possibilities for comparing as yet un-
discovered mechanisms involved in de novo resistance
in patients with acquired resistance.
Pazopanib kinase selectivity (IC50) shows a specific
pattern, with similarities to other TKIs such as sunitinib
(inhibition of c-KIT and PDGFRα and β) sorafenib
(inhibition of c-Raf) or both (inhibition of VEGFRs) [32].
Currently, pazopanib is used as a second-line treatment inpatients with clear-cell RCC that relapses after the admin-
istration of sunitinib or bevacizumab [24]. The efficacy of
pazopanib compared with that of sunitinib remains un-
clear, although there is an ongoing clinical trial comparing
the effects of the two drugs in locally advanced and/or
metastatic RCC in patients with no prior treatment [24].
However, given the specific kinase inhibition pattern of
pazopanib compared with that of sunitinib or sorafenib, it
would be interesting to assay the effects of this drug in
different tumors at the preclinical and clinical stages. The
present study shows that pazopanib as a single agent is
also effective and significantly inhibits growth of two
different testicular GCTs orthotopically grown in nude
mice, a cisplatin-sensitive choriocarcinoma and a yolk sac
metastatic cisplatin-refractory tumor. This growth inhib-
ition is associated in both tumors with a reduction in
tumor vessel density, clearly indicating an anti-angiogenic
effect. Moreover, in our xenografts, tumoral testicular cells
also express some of the pazopanib targets, such as c-KIT
and PDGFR α and β in TGT44, and both PDGFRs in
TGT38, which also suggests a direct anti-tumoral effect in
our in vivo models. In fact, cell cultures of testicular cancer
cells sensitive or resistant to cisplatin respond to pazopanib
by blocking cell growth (data not shown), confirming
this direct anti-tumoral effect. Taken together, our results
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growth by a combination of effects comprising indirect
anti-angiogenic and direct anti-tumoral activity in tes-
ticular cells.
The treatment of relapsed or CDDP-refractory GCT
patients remains a clinical challenge. The options for
these patients include surgery, radiotherapy and the use
of conventional-dose or high-dose chemotherapy, but their
prognosis is generally poor [4,5], highlighting the need
for new, alternative therapies. Anti-angiogenic therapy
has been proposed as a strategy for treating testicular
GCTs [11,33], and successful results have already been
obtained in preclinical models treated with sunitinib,
as reported by Castillo-Ávila et al. [26] and Oechsle
et al. [34], or with other anti-angiogenic compounds
[35,36]. Sunitinib as a single agent was tested in two
clinical trials of refractory GCT [34,37], giving modest
results, with only a few cases of short-duration disease
stabilization followed by rapid progressive disease in
one study [37], but with three temporary partial responses
(9%) and 41% of cases of stable disease [34] in the other.
Moreover, there was a decrease in the frequency of tumor
markers following sunitinib treatment, suggesting that the
targets of sunitinib may still be important to GCT biology
[37]. In fact, a recent study assessing the efficacy of the
combination of oxaliplatin and bevazucimab recorded a
substantial number of responses, clearly more than found
in previous studies in which oxaliplatin alone was used
[38]. This suggests that the use of compounds targeting
VEGF might enhance the performance of chemotherapy
in the treatment of GCTs. It is important to point out that
both tumors analyzed in the present study, in which
pazopanib is shown to be effective, were both positive for
some pazopanib targets. This suggests that only those pa-
tients whose tumors are positive for the specific targets of
these inhibitors may benefit from their effects.
Our results also show a clear synergistic effect of
pazopanib when administered in combination with
lapatinib, a dual anti-ErbB1 and anti-ErbB2 inhibitor. As
we previously described [31], lapatinib alone partially blocks
tumor growth, but does not affect angiogenesis. In contrast,
pazopanib alone or in combination with lapatinib has the
same anti-angiogenic effect, ruling out the possibility of an
indirect anti-angiogenic effect arising from anti-ErbB ther-
apy in this model. This result, and the observed synergistic
effect on tumor volume, indicates independent targets and
effects on tumoral growth for both inhibitors. A similar
effect has been seen when inhibitors for all pathways were
combined, for example in xenograft models of head and
neck tumors [39], non-small cell lung cancers [40] and in
breast cancer brain metastases [41]. Some dual anti-VEGFR
and anti-ErbB inhibitors, such as vandetanib [42], AEE788
[43] and SKLB1206 [44], have been developed and assayed,
with promising results. The combination of lapatinib andpazopanib has also been assayed in various carcinoma cell
lines and shown to have synergistic proapoptotic effects
[45]. In contrast, phase II clinical trials in cervical cancer
and ErbB2-positive breast cancer patients detected toxicity
when the two drugs were combined [46,47]. In the near
future it will be essential to determine whether less toxic
combinatory doses are also effective in patients.
Conclusions
Although the true activity of the various VEGFR inhibitors
in GCTs remains to be demonstrated [37], we believe that
pazopanib is potentially a new agent that merits clinical
testing in CDDP-refractory GCT patients as a single agent
or in combination with other therapies, such as ErbB-
targeted therapies.
Additional file
Additional file 1: Figure S1. A) Mouse body weight throughout
treatment. B) Apoptotic cell detection by TUNEL staining was performed
in liver sections from control and combined drug treatment. Positive
TUNEL cells are pointed with black arrows. Results obtained showed no
difference between control and treated conditions and all liver samples
presented ratios of 0.1-0.5 ‰ positive TUNEL cells. TGT38 tumor treated
with lapatinib was used as positive control. Bar 50 μm, 400X.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MJ carried out the experimental part of this study and helped write the
manuscript. A Vidal carried out the immunohistochemistry and was involved
in drafting the manuscript. XGM helped design the study. JMP helped
design the study. EC helped design the study. OC helped design the study
and drafted the manuscript. MG helped design the study and drafted the
manuscript. JRG helped design the study. A Villanueva generated the mouse
models used in this study and helped write the manuscript. FV helped
design the study, draft and write the manuscript. All authors have read and
approved the final manuscript.
Acknowledgements
This study was supported by research grants from the Ministerio de Ciencia
y Tecnología (SAF2007-60955 and SAF2010-20859), the Spanish Ministry of
Health (RTICC RD2006-0092) and the Generalitat de Catalunya (2005SGR727
and 2009SGR283) to F. Viñals, the Spanish Ministry of Health (FIS PI10-0222)
to A. Villanueva, and the Fundació La Marató de TV3 (051430 to FV and
XGM). MJ is a recipient of a pre-doctoral fellowship from IDIBELL. This study
was partially supported by an unrestricted research grant from
GlaxoSmithKline.
Author details
1Laboratori de Recerca Translacional, Institut Català d'Oncologia, Hospital
Duran i Reynals, 08908 L’Hospitalet de Llobregat, Barcelona, Spain. 2Servei
d’Oncologia Mèdica, Institut Català d’Oncologia, Hospital Duran i Reynals,
08908 L’Hospitalet de Llobregat, Barcelona, Spain. 3Servei d’Anatomia
Patològica, Hospital Universitari de Bellvitge, 08908 L’Hospitalet de Llobregat,
Barcelona, Spain. 4Laboratori d’Oncologia Molecular, Institut d’Investigació
Biomèdica de Bellvitge (IDIBELL), 08908 L’Hospitalet de Llobregat, Barcelona,
Spain. 5Departament de Ciències Fisiològiques II, Universitat de Barcelona,
08908 L’Hospitalet de Llobregat, Barcelona, Spain. 6Departament de
Patologia i Terapèutica Experimental, Universitat de Barcelona, 08908
L’Hospitalet de Llobregat, Barcelona, Spain. 7Institut d’Investigació Biomèdica
de Bellvitge (IDIBELL), 08908 L’Hospitalet de Llobregat, Barcelona, Spain.
Juliachs et al. BMC Cancer 2013, 13:382 Page 9 of 10
http://www.biomedcentral.com/1471-2407/13/382Received: 14 January 2013 Accepted: 2 August 2013
Published: 10 August 2013
References
1. Garner MJ, Turner MC, Ghadirian P, Krewski D: Epidemiology of testicular
cancer: an overview. Int J Cancer 2005, 116(3):331–339.
2. Ulbright TM: Germ cell tumors of the gonads: a selective review
emphasizing problems in differential diagnosis, newly appreciated, and
controversial issues. Mod Pathol 2005, 18(Suppl 2):S61–S79.
3. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ: Medical treatment of
advanced testicular cancer. Jama 2008, 299(6):672–684.
4. Koychev D, Oechsle K, Bokemeyer C, Honecker F: Treatment of patients
with relapsed and/or cisplatin-refractory metastatic germ cell tumours:
an update. Int J Androl 2011, 34(4 Pt 2):e266–e273.
5. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M,
Bodrogi I, Bokemeyer C, Cavallin-Stahl E, et al: European consensus
conference on diagnosis and treatment of germ cell cancer: a report of
the second meeting of the European Germ Cell Cancer Consensus
Group (EGCCCG): part II. Eur Urol 2008, 53(3):497–513.
6. Oldenburg J, Wahlqvist R, Fossa SD: Late relapse of germ cell tumors.
World J Urol 2009, 27(4):493–500.
7. Hanahan D, Folkman J: Patterns and emerging mechanisms of the
angiogenic switch during tumorigenesis. Cell 1996, 86(3):353–364.
8. Carmeliet P: Angiogenesis in life, disease and medicine. Nature 2005, 438
(7070):932–936.
9. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D: Benefits of
targeting both pericytes and endothelial cells in the tumor vasculature
with kinase inhibitors. J Clin Invest 2003, 111(9):1287–1295.
10. Carmeliet P, Jain RK: Molecular mechanisms and clinical applications of
angiogenesis. Nature 2011, 473(7347):298–307.
11. Piulats FGdM JM, Germà Lluch JR: New drugs in the treatment of germ
cell tumors. Cancer Chemoth Rev 2007, 2:232–240.
12. McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ,
Dennis N, Fisher C, Huddart R, Cooper C, et al: Amplification and
overexpression of the KIT gene is associated with progression in the
seminoma subtype of testicular germ cell tumors of adolescents and
adults. Cancer Res 2005, 65(18):8085–8089.
13. Basciani S, Mariani S, Arizzi M, Ulisse S, Rucci N, Jannini EA, Della Rocca C,
Manicone A, Carani C, Spera G, et al: Expression of platelet-derived growth
factor-A (PDGF-A), PDGF-B, and PDGF receptor-alpha and -beta during
human testicular development and disease. J Clin Endocrinol Metab 2002,
87(5):2310–2319.
14. Jones A, Fujiyama C, Turner K, Fuggle S, Cranston D, Turley H, Valtola R,
Bicknell R, Harris AL: Angiogenesis and lymphangiogenesis in stage 1
germ cell tumours of the testis. BJU Int 2000, 86(1):80–86.
15. Aigner A, Brachmann P, Beyer J, Jager R, Raulais D, Vigny M, Neubauer A,
Heidenreich A, Weinknecht S, Czubayko F, et al: Marked increase of the
growth factors pleiotrophin and fibroblast growth factor-2 in serum of
testicular cancer patients. Ann Oncol 2003, 14(10):1525–1529.
16. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC,
Hopper TM, Miller CG, Harrington LE, Onori JA, et al: Pharmacokinetic-
pharmacodynamic correlation from mouse to human with pazopanib,
a multikinase angiogenesis inhibitor with potent antitumor and
antiangiogenic activity. Mol Cancer Ther 2007, 6(7):2012–2021.
17. Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG,
Epperly AH, Hinkle KW, Hunter RN 3rd, Johnson JH, et al: Discovery of
5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]
amino]-2-m ethyl-benzenesulfonamide (Pazopanib), a novel and
potent vascular endothelial growth factor receptor inhibitor. J Med
Chem 2008, 51(15):4632–4640.
18. Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S,
Kumar R, Pandite LN, et al: The small-molecule VEGF receptor inhibitor
pazopanib (GW786034B) targets both tumor and endothelial cells in
multiple myeloma. Proc Natl Acad Sci U S A 2006, 103(51):19478–19483.
19. Schutz FA, Choueiri TK, Sternberg CN: Pazopanib: Clinical development of
a potent anti-angiogenic drug. Crit Rev Oncol Hematol 2010, 77(3):163–171.
20. Bible KC, Suman VJ, Molina JR, Smallridge RC, Maples WJ, Menefee ME,
Rubin J, Sideras K, Morris JC 3rd, McIver B, et al: Efficacy of pazopanib in
progressive, radioiodine-refractory, metastatic differentiated thyroid
cancers: results of a phase 2 consortium study. Lancet Oncol 2010,
11(10):962–972.21. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schoffski P, Collin F,
Pandite L, Marreaud S, De Brauwer A, et al: Pazopanib, a multikinase
angiogenesis inhibitor, in patients with relapsed or refractory advanced
soft tissue sarcoma: a phase II study from the European organisation for
research and treatment of cancer-soft tissue and bone sarcoma group
(EORTC study 62043). J Clin Oncol 2009, 27(19):3126–3132.
22. Socinski MA: Multitargeted receptor tyrosine kinase inhibition: An
antiangiogenic strategy in non-small cell lung cancer. Cancer Treat Rev
2011, 37(8):611–617.
23. Burger RA: Overview of anti-angiogenic agents in development for
ovarian cancer. Gynecol Oncol 2011, 121(1):230–238.
24. Rini B, Al-Marrawi MY: Pazopanib for the treatment of renal cancer. Expert
Opin Pharmacother 2011, 12(7):1171–1189.
25. Bukowski RM, Yasothan U, Kirkpatrick P: Pazopanib. Nat Rev Drug Discov
2010, 9(1):17–18.
26. Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E,
Casanovas O, Mora J, Germa JR, Capella G, Villanueva A, et al: Sunitinib
inhibits tumor growth and synergizes with cisplatin in orthotopic
models of cisplatin-sensitive and cisplatin-resistant human testicular
germ cell tumors. Clin Cancer Res 2009, 15(10):3384–3395.
27. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith
KJ, Guntrip SB, Carter MC, Shaw RJ, et al: The characterization of novel,
dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for
cancer. Cancer Res 2001, 61(19):7196–7203.
28. Guerin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi
MC, Merlano M, Ferrero JM, Milano G: Supra-additive antitumor effect of
sunitinib malate (SU11248, Sutent) combined with docetaxel. A new
therapeutic perspective in hormone refractory prostate cancer. J Cancer
Res Clin Oncol 2008, 134(1):51–57.
29. Pera MF, Blasco Lafita MJ, Mills J: Cultured stem-cells from human
testicular teratomas: the nature of human embryonal carcinoma, and
its comparison with two types of yolk-sac carcinoma. Int J Cancer
1987, 40(3):334–343.
30. Vogelzang NJ, Bronson D, Savino D, Vessella RL, Fraley EF: A human
embryonal-yolk sac carcinoma model system in athymic mice.
Cancer 1985, 55(11):2584–2593.
31. Juliachs M, Castillo-Avila W, Vidal A, Piulats JM, Del Muro XG, Condom E,
Hernandez-Losa J, Teixido C, Pandiella A, Graupera M, et al: ErbBs inhibition
by lapatinib blocks tumor growth in an orthotopic model of human
testicular germ cell tumor. Int J Cancer 2013, 133(1):235–246.
32. Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin
RA, King AG: Myelosuppression and kinase selectivity of multikinase
angiogenesis inhibitors. Br J Cancer 2009, 101(10):1717–1723.
33. Fenner MH, Beutel G, Grunwald V: Targeted therapies for patients with
germ cell tumors. Expert Opin Investig Drugs 2008, 17(4):511–522.
34. Oechsle K, Honecker F, Cheng T, Mayer F, Czaykowski P, Winquist E, Wood L,
Fenner M, Glaesener S, Hartmann JT, et al: Preclinical and clinical activity of
sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell
tumors: a Canadian Urologic Oncology Group/German Testicular Cancer
Study Group cooperative study. Ann Oncol 2011, 22(12):2654–2660.
35. Nitzsche B, Gloesenkamp C, Schrader M, Ocker M, Preissner R, Lein M,
Zakrzewicz A, Hoffmann B, Hopfner M: Novel compounds with
antiangiogenic and antiproliferative potency for growth control of
testicular germ cell tumours. Br J Cancer 2010, 103(1):18–28.
36. Nitzsche B, Gloesenkamp C, Schrader M, Hoffmann B, Zengerling F,
Balabanov S, Honecker F, Hopfner M: Anti-tumour activity of two novel
compounds in cisplatin-resistant testicular germ cell cancer. Br J Cancer
2012, 107(11):1853–1863.
37. Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, Bosl GJ,
Motzer RJ: Phase II trial of sunitinib in patients with relapsed or
refractory germ cell tumors. Invest New Drugs 2010, 28(4):523–528.
38. Jain A, Brames MJ, Vaughn DJ, Einhorn LH: Phase II clinical trial of
oxaliplatin and bevacizumab in refractory metastatic germ cell tumors
(GCT). J Clin Oncol 2011, 29(suppl; abstr 4579):2011.
39. Bozec A, Formento P, Lassalle S, Lippens C, Hofman P, Milano G: Dual
inhibition of EGFR and VEGFR pathways in combination with irradiation:
antitumour supra-additive effects on human head and neck cancer
xenografts. Br J Cancer 2007, 97(1):65–72.
40. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits
E, Byers LA, Xu L, Wu HK, et al: Combined vascular endothelial growth
factor receptor and epidermal growth factor receptor (EGFR) blockade
Juliachs et al. BMC Cancer 2013, 13:382 Page 10 of 10
http://www.biomedcentral.com/1471-2407/13/382inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Clin Cancer Res 2009, 15(10):3484–3494.
41. Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, Farrar
CT, Huang Y, Ager E, Kamoun W, et al: Combined targeting of HER2 and
VEGFR2 for effective treatment of HER2-amplified breast cancer brain
metastases. Proc Natl Acad Sci U S A 2012, 109(45):E3119–E3127.
42. Ciardiello F, Caputo R, Damiano V, Troiani T, Vitagliano D, Carlomagno F,
Veneziani BM, Fontanini G, Bianco AR, Tortora G: Antitumor effects of
ZD6474, a small molecule vascular endothelial growth factor receptor
tyrosine kinase inhibitor, with additional activity against epidermal growth
factor receptor tyrosine kinase. Clin Cancer Res 2003, 9(4):1546–1556.
43. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K,
Lane HA, McSheehy P, Mestan J, et al: AEE788: a dual family epidermal
growth factor receptor/ErbB2 and vascular endothelial growth factor
receptor tyrosine kinase inhibitor with antitumor and antiangiogenic
activity. Cancer Res 2004, 64(14):4931–4941.
44. Pan Y, Xu Y, Feng S, Luo S, Zheng R, Yang J, Wang L, Zhong L, Yang HY,
Wang BL, et al: SKLB1206, a novel orally available multikinase inhibitor
targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and
VEGFR2, displays potent antitumor activity both in vitro and in vivo.
Mol Cancer Ther 2012, 11(4):952–962.
45. Olaussen KA, Commo F, Tailler M, Lacroix L, Vitale I, Raza SQ, Richon C,
Dessen P, Lazar V, Soria JC, et al: Synergistic proapoptotic effects of the
two tyrosine kinase inhibitors pazopanib and lapatinib on multiple
carcinoma cell lines. Oncogene 2009, 28(48):4249–4260.
46. Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W,
Alber JA, Ding J, Stutts MW, Pandite LN: Phase II, open-label study of
pazopanib or lapatinib monotherapy compared with pazopanib plus
lapatinib combination therapy in patients with advanced and recurrent
cervical cancer. J Clin Oncol 2010, 28(22):3562–3569.
47. Cristofanilli M, Johnston SR, Manikhas A, Gomez HL, Gladkov O, Shao Z,
Safina S, Blackwell KL, Alvarez RH, Rubin SD, et al: A randomized phase II
study of lapatinib + pazopanib versus lapatinib in patients with HER2+
inflammatory breast cancer. Breast Cancer Res Treat 2012, 137(2):471–482.
doi:10.1186/1471-2407-13-382
Cite this article as: Juliachs et al.: Effectivity of pazopanib treatment in
orthotopic models of human testicular germ cell tumors. BMC Cancer
2013 13:382.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
